Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-02-21
1999-11-30
Campell, Bruce R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 2, 514 8, 435458, 424 88, 424401, 424450, 4241841, 424121, 264 46, H61K 4800
Patent
active
059943181
ABSTRACT:
The instant disclosure relates to cochleates comprising a) a biologically relevant molecule component b) a negatively charged lipid component, and c) a divalent cation component. The cochleate has an extended shelf life, even in a desiccated state. Advantageously, the cochleate can be ingested. The biologically relevant molecule can be a topical application and an in vitro treatment, a polypeptide a drug, a nutrient, or a flavor.
REFERENCES:
patent: 4078052 (1978-03-01), Papahadjopoulos
patent: 4663161 (1987-05-01), Mannino et al.
patent: 4725442 (1988-02-01), Haynes
patent: 4871488 (1989-10-01), Mannino et al.
patent: 4874795 (1989-10-01), Yesair
patent: 4906476 (1990-03-01), Radhakrishnan
patent: 5026557 (1991-06-01), Estis
patent: 5190760 (1993-03-01), Baker
patent: 5409698 (1995-04-01), Anderson
patent: 5484589 (1996-01-01), Salganik
patent: 5529914 (1996-06-01), Hubbell et al.
patent: 5571517 (1996-11-01), Yesair
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5603931 (1997-02-01), Raso
patent: 5612019 (1997-03-01), Gordon et al.
Booser et al., Anthracycline antibiotics in cancer therapy. Drugs 47:223-258, 1994.
Mori et al., Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Pharmaceutical 10:507-514, 1993.
Liposome Technology, 2nd Ed., vol. 1, G. Gregoriadis, "Liposome preparation and related techniques" published 1993 by CRC Press, Inc., (Boca Raton), pp. 67-80.
Miller et al., Vaccination of Rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes. J.Exp.Med. 176:1739-1744, 1992.
Deres et al., In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561-564, 1989.
Gould-Fogerite et al., Chimerasome-mediated gene transfer in vitro and in vivo. Gene 84:429-438, 1989.
Papahadjopoulos et al., Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochimica et Biophysica Acta 394:483-491, 1975.
Gould-Fogerite et al., Rotary dialysis: its application to the preparation of large liposomes and large proteoliposomes (protein-lipid vesicles) with high encapsulation efficiency abd efficient reconstitution of membrane proteins. Analytical Biochem. 148:15-25, 1985.
Kim et al., Advances in membrane biochemistry and bioenergetics, published 1988 by Plenum Publishing Corporation, pp. 569-586.
R.J. Mannino and S. Gould-Fogerite, Liposome mediated gene transfer. BioTechniques 6:682-690, 1988.
Gould-Fogerite et al., The reconstitution of biologically active glycoproteins into large liposomes: use as a delivery vehicle to animal cells. Advances in Membrane Biochemistry and Bioenergetics, pp. 569-586, 1988.
Gould-Fogerite and Mannino, Liposome preparation and related techniques. Liposome Technology 2nd Ed., vol. I, pp. 67-80.
Gould-Fogerite and Mannino, Entrapment of drugs and other materials. Liposome Technology 2nd Ed., vol. II, pp. 167-184.
Gould-Fogerite and Mannino, Interaction of liposomes with the biological milieu. Liposome Technology 2nd Ed., vol. III, pp. 261-276.
Goodman-Snitkoff et al., Defining minimal requirements for antibody production to peptide antigens. Vaccine 8:257-262, 1990.
Goodman-Snitkoff et al., Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes. J.Immunol. 147:410-415, 1991.
Krowka, J.Immunol. 144:2535, 1990.
Wassely, Immunol.Methods 4:217, 1994.
Oleske et al., Autogenous vaccine treatment of laryngeal papilloma. Curr.Chemotherapy and Immunotherapy, Proc. 12th Intl. Cong. of Chemotherapy, Florence, Italy, Jul. 19-24, 1981, pp. 1099-1101.
Oleske et al., Juvenile papilloma of the larynx, Am.J. of Diseases of Children 121:417-419, 1971.
Kensil et al., Structure/function relationship in adjuvants from Quillaja saponaria Molina, Vaccines 92, Cold Spring Harbor Laboratory Press, 1992, pp. 35-40.
Kensil et al., The use of stimulation adjuvant to boost vaccine response, Vaccine Research, 2:273-281, 1993.
Newman et al., Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates. AIDS research and human retroviruses 8:1413-1418, 1992.
Wu et al., Accesory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes. Cell.Immunol. 154:393-406, 1994.
Wu et al., Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J.Immunol. 148:1519-1525, 1992.
Newman et al., Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses J.Immunol. 148:2357-2362, 1992.
Kensil et al., Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J.Immunol. 146:431-437, 1991.
Salk, Contakos et al., Use of adjuvants in studies on influenza immunization, J.A.M.A. 151:1169-1175, 1953.
Graham et al., Augmentation of human immunodeficiency virus type 1 neutralzing antibody by printing with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J.Infect.Dis. 167:533-537, 1993.
Celis et al., Regulation of the human immune response to HBsAg: effects of antibodies and antigen conformation in the stimulation of helper T cells by HBsAg. Hepatology 5:744-751, 1985.
Salk, Prospects for the control of AIDS by immunizing seropositive individuals. Nature 327:473-476, 1987.
Bisaccia et al., Extracorporeal photopheresis in the treatment of AIDS-related complex: a pilot study Annals of Internal Medicine 113:270-275, 1990.
Lanzavecchia et al., T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature 334:530-534, 1988.
McDougal et al., Antibody response to human immunodeficiency virus in homosexual men. J.Clin.Invest. 80:316-324, 1987.
Belshe et al., Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J.Infect.Dis. 168:1387-1395, 1993.
Walker et al., HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345-348, 1987.
Stanhope et al., Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J.Infect.Dis. 168:92-100, 1993.
Beretta et al., HIV env glycoprotein shares a cross-reacting epitope with a surface protein present on activated human monocytes and involved in antigen presentation. Eur.J.Immunol. 17:1793-1798, 1987.
Golding et al., Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA Class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J.Clin.Invest. 83:1430-1435, 1989.
De Santis et al., Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA Class I heavy chains induced by receipt of HIV-1 derived envelope vaccines. J.Infect.Dis. 168: 1396-1403, 1993.
Redfield et al., Psoralen inactivation of influenza and herpes simplex viruses and of virus-infected cells. Infect.Immun. 32:1216-1226, 1981.
Livingston et al., Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines. Annals New York Academy of Sciences, pp. 204-213.
Gold et al., Viagene begins new gene therapy trial. Treatment Issues 8:5-13.
Darrow et al., Immunotherapy of human melanoma with gene-modified tumor cell vaccines. Cancer Control pp. 415-428, Sep./Oct. 1995.
Wain-Hobson, Virological Mayhem, News and Views.
Bernengo et al., The in vitro effect of calf thymus extract on the peripheral blood lymphocytes of patients with warts. British J.Derm. 102:11-16, 1980.
Ingimarsson et al., Side effects of long-term treatment with human leukocyte inteferon. J.Infect.Dis. 140:560-563, 1979.
Scott et al., Effect of injections of small doses of human fibroblast interferon into genital warts. British J. Venereal Diseases 55:442-445, 1979.
Soltysik et al., Adjuvant activity of QS-21 isomers. Annals of the New York Academy of Sciences 690: 392-395, 1993.
White et al., A purified saponin acts as an adjuvant for a T-independent antigen. Immunobiol.
Gould-Fogerite Susan
Mannino Raphael James
Albany Medical College
Campell Bruce R.
Nguyen Dave Trong
University of Medicine and Dentistry of New Jersey
LandOfFree
Cochleate delivery vehicles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cochleate delivery vehicles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cochleate delivery vehicles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1672690